相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials
Shomron Ben-Horin et al.
GASTROENTEROLOGY (2022)
What is the Real Impact of Corticosteroids in the Contemporary Treatment of Crohn's Disease?
Karime Lucas Uemura et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Jason J. Luke et al.
LANCET (2022)
Triple combination of ipilimumab plus nivolumab plus anti-TNF in treatment naive melanoma patients: Final analysis of TICIMEL, a phase Ib prospective clinical trial
N. Meyer et al.
ANNALS OF ONCOLOGY (2022)
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma
Olivier J. van Not et al.
JAMA ONCOLOGY (2022)
Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis
David M. Faleck et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
Anne Montfort et al.
CLINICAL CANCER RESEARCH (2021)
EFFICACY OF INFLIXIMAB DOSE ESCALATION IN PATIENTS WITH REFRACTORY IMMUNOTHERAPY-RELATED COLITIS: A CASE SERIES
Jessica Harris et al.
INFLAMMATORY BOWEL DISEASES (2021)
Understanding and treating the inflammatory adverse events of cancer immunotherapy
Michael Dougan et al.
CELL (2021)
Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events
Jia Luo et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Association of Anti-Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease
Shirley Cohen-Mekelburg et al.
JAMA NETWORK OPEN (2021)
Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis
Ju Li et al.
FRONTIERS IN PHARMACOLOGY (2021)
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy
Xue Bai et al.
CLINICAL CANCER RESEARCH (2021)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R. Brahmer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study
Fangwen Zou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data
Russell D. Cohen et al.
JOURNAL OF CROHNS & COLITIS (2020)
Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry
Rik J. Verheijden et al.
CLINICAL CANCER RESEARCH (2020)
TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?
Jeffrey S. Weber et al.
CLINICAL CANCER RESEARCH (2020)
Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review
Michael Collins et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management
Hamzah Abu-Sbeih et al.
CURRENT OPINION IN GASTROENTEROLOGY (2020)
The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease
Alexander M. Dorrington et al.
JOURNAL OF CROHNS & COLITIS (2020)
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
Adrienne M. Luoma et al.
CELL (2020)
Infliximab in acute severe colitis: getting the right dose
Joseph Fiske et al.
FRONTLINE GASTROENTEROLOGY (2020)
Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis
Hajir Ibraheim et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Management of Immunotherapy-Related Toxicities. Version 1.2019
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Infliximab in inflammatory bowel disease
Konstantinos Papamichael et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2019)
The Role of Early Biologic Therapy in Inflammatory Bowel Disease
Dana Rachel Berg et al.
INFLAMMATORY BOWEL DISEASES (2019)
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
V. Ellen Maher et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis
Hamzah Abu-Sbeih et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis
Matthew C. Choy et al.
INFLAMMATORY BOWEL DISEASES (2019)
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
Filipe Martins et al.
LANCET ONCOLOGY (2019)
Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease
James D. Lewis et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management
Mark A. Samaan et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Vedolizumab for inflammatory bowel disease: from randomized controlled trials to real-life evidence
Maria Lia Scribano
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
Yinghong Wang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials
Bo Zhang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Yinghong Wang et al.
NATURE MEDICINE (2018)
Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
Daniel H. Johnson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
Mario Sznol et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
Florie Bertrand et al.
NATURE COMMUNICATIONS (2017)
Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study
Akbar K. Waljee et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study
Akbar K. Waljee et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Long-term side effects of glucocorticoids
Merih Oray et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Ipilimumab-induced colitis: experience from a tertiary referral center
Anthony O'Connor et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2016)
Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis
M. J. Rosen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Omar Abdel-Rahman et al.
IMMUNOTHERAPY (2015)
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
TNF signaling drives myeloid-derived suppressor cell accumulation
Xueqiang Zhao et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis
Tiziana Schioppa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
S. J. O'Day et al.
ANNALS OF ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab
R. L. Johnston et al.
DIGESTIVE DISEASES AND SCIENCES (2009)
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial
Geert D'Haens et al.
LANCET (2008)
Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells
Xin Chen et al.
JOURNAL OF IMMUNOLOGY (2007)
分享论文
